© 2026 Sinochem Nanjing Corporation,
All Right Reserved
|
HS Code |
408505 |
As an accredited 2-Bromo-3-Pyridinecarboxylic Acid Methyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 2-Bromo-3-Pyridinecarboxylic Acid Methyl Ester prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Every medicinal chemist learns quickly that some molecules change the outlook for an entire project. 2-Bromo-3-Pyridinecarboxylic Acid Methyl Ester, CAS number 15862-07-4, stands out during those first exploratory steps and deserves some close attention for what it brings to the bench.
Getting familiar with its basic model starts at the bench. The compound appears as a pale yellow to off-white solid, which can be weighed directly and dissolves smoothly into common organic solvents during reaction setup. The 98% purity version lands in the sweet spot—reliable quality with minimal batch-to-batch variability, offering a clear signal in spectral characterizations. Methyl ester functionalization adds a handy point for subsequent transformations, saving time for those aiming to streamline multi-step synthesis.
Anyone who has spent a week running aromatic substitutions knows the frustration with reluctant pyridines. The 2-bromo position creates an especially reactive handle. That makes cross-coupling much less of a headache than using similar molecules with chloro or fluoro leaving groups. In Suzuki or Buchwald-Hartwig reactions, this ester performs with a level of confidence that encourages risk-taking on more ambitious routes. The methyl ester protects the carboxyl group during palladium-catalyzed transformations, tolerating conditions that usually spell trouble.
In my own workflow, I recall the advantage this methyl ester gave in avoiding protection-deprotection chaos. Out of several screened pyridinecarboxylic acids, the methyl ester powered through ester-intact amidations and only needed saponification right at the last step. Yields beat my early projections, and I didn’t spend late evenings running column after column to scrub away hydrolysis byproducts.
2-Bromo-3-pyridinecarboxylic acid methyl ester’s core structure—bromine at position 2 and methyl ester at position 3—should not be underestimated. The bromine atom’s size and electron-withdrawing power accelerates cross-coupling in comparison to chloride analogs. In palladium-catalyzed routes, those extra percentage points of conversion can mean the difference between a project milestone and a missed deadline. The methyl ester’s resilience means you can push a range of reaction conditions without constantly worrying about hydrolysis.
I’ve seen projects where swapping an ethyl ester for methyl led straight to a three-way tie between yield, conversion, and waste management headaches. The methyl group’s compactness and lower propensity for transesterification sidesteps such issues in most common protocols. What seals the deal is the spectral clarity; NMR and mass spectrometry data present clean shifts and peaks, making characterization less of a puzzle—especially at scale.
Sustainable chemistry only works if it fits into real-world synthetic plans and delivers consistent results on scale-up. Here, 2-bromo-3-pyridinecarboxylic acid methyl ester finds a place in both academic and commercial settings. Less time spent on purification translates directly to reduced solvent use. In the past year, as environmental compliance and solvent recycling have tightened up, even mid-size labs now see the cost savings in reduced waste from simplified post-reaction work-ups.
Talking with colleagues running scale-ups in pharmaceutical process development, many share frustration with batch inconsistencies from less pure starting materials or those requiring additional purification steps—either due to colored impurities or persistent byproducts. The standard 98% purity of this product out of the bottle means fewer hours wasted on recrystallization. Financial controllers don't often appreciate this detail, but synthetic chemists know a pure input means a cleaner output downstream and less downtime dealing with surprises in the kilo lab.
Drug discovery projects put pressure on route flexibility. When a team needs to rapidly build analog libraries, the ability to selectively modify points on the pyridine ring guides career-defining decisions. This compound sits at a rare intersection—stable under ambient conditions, yet reactive enough for a diversity of cross-coupling, ester hydrolysis, and amidation strategies. In the last decade, research groups probing kinase inhibitors or CNS-active agents rely on the 2-bromo position for developing new motifs, merging the pyridine’s aromatic properties with diverse side chains.
Colleagues in natural product synthesis routinely mention the ability to incorporate this ester late in a pathway, where less robust functional groups would derail weeks of effort. Its resistance to hydrolysis under moderate conditions allows for advanced intermediates to reach the finish line. Small startups focused on early-stage SAR work have sent back the same reviews: their chemists trust this building block to carry critical functional groups intact through the required steps.
Comparisons matter in route design. The simplest alternative, 3-pyridinecarboxylic acid methyl ester without the 2-bromo handle, suffers from less control in late-stage diversification. Unsubstituted at the 2-position, it tends to favor less selective transformation, hampering regioselective chemistry and making purification a struggle. The bromo group gives chemists a clear target for Suzuki couplings, enabling more straightforward late-stage diversification.
Many reach for the 2-chloro-3-pyridinecarboxylic acid methyl ester as a supposed alternative, drawn in by a slightly lower entry price. Chirality isn’t an issue, but reaction rates with palladium catalysts lag behind the bromo derivative, and yields frequently take a hit. Going beyond halides, the free acid form sacrifices stability—hydrolysis and accidental decarboxylation sideline plans and force laborious re-optimization of conditions. Esterification with other groups such as tert-butyl stokes environmental concern around persistent organic pollutants, a challenge less pronounced for methyl esters.
Every synthetic route begins with safe handling and dependable storage. This compound holds up in dry, cool environments—extended shelf life means less batch purchasing and waste. I’ve had the same lot in my chemical cabinet for over a year without visible degradation or signal drift on HPLC checks. Spill mitigation is straightforward: the solid’s low volatility and defined melting point reduce inhalation risk, which can’t be said for liquid intermediates or more volatile analogs. This stability gives peace of mind to academic groups where turnover in personnel can sometimes mean less experienced hands on inventory.
Any product heading into process synthesis must clear regulatory and analytical hurdles. 2-bromo-3-pyridinecarboxylic acid methyl ester stands tall under routine purity checks (NMR, GC-MS, HPLC), facilitating easy method development and rapid transfer between development and production teams. Environmental health and safety officers have less paperwork when a building block balances high chemical utility with low hazard rating by global regulatory matrices.
My own experience tells me that the very features making this methyl ester valuable can sometimes amplify risk during scale-up. The bromine atom means trace levels in effluents must be managed well. Savvy labs have invested in halide capture protocols tailored for bromo-aromatics, reducing waste management headaches. It pays to anticipate this step in early planning, partnering with commercial waste processors able to handle such effluents in line with updated local environmental regulations.
Another point to watch is cost volatility due to global bromine sourcing. The price sometimes jumps with geopolitical interruptions or commodity swings. Research groups planning long synthetic campaigns benefit from building buffer stock or developing flexible intermediates to bridge gaps. On more than one project, I’ve seen teams who couldn’t get the right batch mid-project forced into last-minute route redesigns, eating up months of work. Reliable suppliers with transparent track records mitigate this risk, but it pays to keep an ear out for supply chain updates and emerging alternatives.
The optimal workflow integrates this methyl ester early so that downstream manipulations align with the compound’s strengths. For medicinal chemists, modular parallel synthesis becomes more efficient: using automated platforms, I’ve queued up side-by-side couplings where the bromo handle selects for ortho substitution and the methyl ester remains untouched until just before final purification. Maintaining consistency in solvent quality and palladium loading ensures conversion doesn’t dip batch-to-batch.
Scale-up teams demonstrate gains by introducing in-line purification for post-coupling mixtures, capitalizing on the methyl ester’s relative polarity to trim down chromatographic steps. Quality assurance gains come from systematic use of validated purity data, reducing re-testing and rerun rates across the pilot plant and final production lines. In the broader context, advocating for sustainable bromine capture and closed-loop solvent recycling builds both environmental credentials and operational savings.
Watching the evolution of fine chemical markets, demand for this methyl ester tracks with increased focus on heterocyclic motifs in small-molecule therapeutics. Patent filings echo this trend, with the pyridine core seen in new kinase inhibitors, antibacterial agents, and agrochemicals each year. Regulatory scrutiny increasingly focuses on trace contaminants and process residuals, which benefits intermediates like this with clear analytical profiles and controllable impurity ladders.
Anecdotes from marketing teams at analytical reagent suppliers say that stocks of the 98% pure methyl ester turn over twice as fast as comparable halogenated pyridines in the same purity range. More importantly, custom synthesis firms cite client satisfaction rates that track with this compound’s use as a key intermediate—a nod to fewer project delays, less firefighting at the bench, and more predictable scale-up. Calls for “greener” synthesis have also boosted interest in methyl esters over bulkier alternatives, as mounting documentation shows their comparative ease of separation and lower environmental impact.
A repeating lesson in pharmaceutical development is the importance of constructive collaboration between discovery chemists and process engineers. 2-Bromo-3-pyridinecarboxylic acid methyl ester stands as a shared language between these domains. Its clear-reactivity profile means that handovers go smoothly; process teams appreciate predictable impurity clearance and regulatory compliance checks, while discovery groups enjoy the flexibility in functionalization.
Having participated in interdisciplinary workshops focused on heterocycle functionalization, I can say the methyl ester often serves as an example of cross-team consensus. Chemists from different regions compare their favorite routes—one group using classic Suzuki couplings, another leveraging direct amidations. In nearly every discussion, focus lands on route robustness and impurity control, reinforced by the methyl ester’s performance in diverse hands. Analytical chemists comment on clean chromatograms with minimal ghost peaks, regulatory scientists mention the ease in writing up dossiers. Teams moving between kilo and pilot scale now cite fewer hiccups, supporting a faster path to market for lead candidates.
Academic instructors in graduate-level organic labs have reported using 2-bromo-3-pyridinecarboxylic acid methyl ester for teaching advanced transformations. Its suitability for multiple strategies—nucleophilic substitution, cross-coupling, and ester hydrolysis—enables students to see real-world chemistry under safe, reproducible conditions. Even as a teaching tool, the methyl ester exposes students to practical challenges in purification and method development. Conversations with students reveal how success on this substrate builds confidence for later independent research.
Literature reviews on synthetic methods using brominated pyridines often highlight the methyl ester’s role in delivering consistent yields and facilitating late-stage C–H activation, expanding the possibilities for protein-interacting motifs and ligand scaffolds. Graduate students appreciate available data on reaction conditions, side-by-side spectral comparisons, and practical tips for work-up. Universities collaborating in multi-center research initiatives have documented reproducibility across geographically diverse sites, a testament to the methyl ester’s robustness.
Project teams screening variation in carboxy side chains for SAR often rely on the methyl ester as a solid starting point, noting reduced reaction times and simplified purification workflows. Medicinal chemists taking on urgent structure-activity projects note that the scope of late-stage modifications increases—by tuning the order of halogen substitution, ester hydrolysis, or amidation, diverse analogs spring from a reliable core. This flexibility allows grant-funded projects to stretch budgets and timelines, turning initial fragments into viable leads with fewer dead ends.
CROs (Contract Research Organizations) highlight that time-to-delivery improves as projects scale up with the methyl ester. Chemistry outsourcing contracts increasingly specify this compound as the preferred tool for new scaffold exploration. Anecdotal evidence from synthetic program managers describes project turnarounds accelerating by as much as several weeks once they shifted from acid or tert-butyl ester analogs to the methyl ester—especially in fragment-based or click-chemistry campaigns.
Compliance with evolving global standards gives organizations an edge for clinical candidates. The tidy analytical footprint of 2-bromo-3-pyridinecarboxylic acid methyl ester means traceability and batch release go more smoothly. Tech transfer from R&D to cGMP manufacturing benefits as the methyl ester’s impurity ladder stands up to inspection with ICH Q3A and Q3C guidelines. Fewer “unknown unknowns” support early, confident regulatory filings and less time spent on forced degradation stress testing.
In conversations with QA auditors, building blocks like this receive praise for their clear safety profiles, with historical toxicological studies showing rapid metabolite clearance and minimal bioaccumulation concerns. Paired with simpler waste handling, project leads see a more predictable route to successful preclinical submissions and early-stage regulatory meetings.
It takes years of lab experience to appreciate how one capable reagent can stitch together an otherwise uncertain synthesis plan. 2-Bromo-3-pyridinecarboxylic acid methyl ester finds friends wherever iterative transformations, robust coupling chemistry, and scale-up resilience converge. The advantages appear at every step: reduced purification time, consistent reactivity, and a manageable safety profile. Feedback from medicinal chemistry, process development, analytical, and regulatory voices repeatedly point to its reliability and adaptability.
In the face of mounting pressure for innovation, safety, and sustainability, this methyl ester sets a realistic benchmark for other fine chemical intermediates. For research teams, small companies, and large-scale manufacturers alike, it builds new opportunities—not only for efficiency and cost savings, but for trusted route development and creative exploration.
